To clarify the correlation between the expression of stem cell markers (CD133 and SOX2) and the prognosis in advanced or metastatic cancer patients, we investigated the relationship between the expression of these two markers and survival of the samples. This evidence concerns the gene SOX2 and metastatic malignant neoplasm.